Effects of Deferoxamine on Fat Graft Survival

Abstract

The most important problem in fat transplantation is the unpredictable rates of resorption. Deferoxamine (DFO) is an iron-chelating agent with many useful functions including stimulating angiogenesis and antioxidant nature. The purpose of the study is to evaluate the effects of DFO on fat graft viability in rat model. A total of 24 Wistar rats were divided into three groups and 0.5 g of the left inguinal fat pad was extracted. In control group, fat grafts were implanted to the parascapular area without performing any procedure. In sham group, they were implanted in 0.2 mL saline solution followed by serial saline injections for 1 month. In the study group, fat grafts were implanted in 0.2 mL saline solution and 300 mg DFO followed by serial DFO injections for 1 month. At the postoperative second month, fat grafts were taken back and sent for histopathologic examination. The weight measurements of biopsy specimens in the study group demonstrated significantly higher than in the other two groups. Inflammation and fibrosis rates were also found to be significantly higher in the study group compared with the other groups; however, no significant difference in the apoptosis rates was detected between the groups. Fat grafts enriched with DFO showed significant increase in fatty tissue content in the study group compared with the control and sham groups. DFO increases the fat graft survival in rats and it may be a useful addition in autologous fat grafting procedures to increase fat graft viability and obtain maximal long-term durability.

Deferoxamine Preconditioning of Irradiated Tissue Improves Perfusion and Fat Graft Retention

“…Importantly, DFO was recently suggested to promote fat graft viability in a rat model. Temiz and colleagues described serial injections of 300 mg DFO into inguinal fat pads transplanted to parascapular subcutaneous pockets, which resulted in significantly greater weight measurements after two months (12). However, more inflammation and fibrosis was noted in DFO injected fat grafts, though no change in cellular apoptosis was appreciated.…”

“…As an alternative, deferoxamine (DFO) has been studied as an angiogenic and antioxidant agent with the potential to improve fat graft survival (12). DFO, an FDA approved iron chelator for treating acute iron poisoning and chronic iron overload associated with frequent blood transfusions, has also been demonstrated to increase hypoxia-inducible factor -1 alpha (HIF-1α) activity and enhance expression of angiogenic growth factors (13, 14).…”

A single‐center blinded randomized clinical trial to evaluate the anti‐aging effects of a novel HSF™‐based skin care formulation

“…Well known as a treatment option for beta‐thalassemia and hemochromatosis, 64,65 iron chelating drugs have shown benefits in aesthetic medicine and plastic surgery. With their regenerative potential, they have the ability to increase the retention rate of fat grafts, the survival rate of free flaps, and the healing process of diabetic wounds 66,67 …”

Fat Chance: The Rejuvenation of Irradiated Skin

“…72,73 Autologous fat grafts enriched with DFO have been shown to have increased graft survival and viability in rats. 74 A concern with intragraft injection of DFO, however, is that it may chelate and thus deplete iron, which can impair adipogenesis. 44,45,75 To circumvent this, preconditioning of irradiated recipient sites with DFO before fat grafting has been performed and we have found that this strategy improved vascularization before grafting, and ultimately enhanced volume of retained fat retained posttransplantation.…”